Biomarin Pharmaceutical

US · BMRN #1379 by market cap Listed 1970

55.20 -1.02 -1.81%

Live - 5344 symbols - heartbeat 222s ago · 2026-10-08 07:00

Pre-market 55.05 -0.27%

After-hours 55.55 +0.63%

Market cap: 10.69B
P/E (TTM): 145.26
P/B: 1.69
EPS: 1.80
Div yield: 0.00%
52W pos: 27%

Reader sentiment Are you bullish or bearish on BMRN?

Anonymous reader poll. Unscientific, not investment advice.

About Biomarin Pharmaceutical

BioMarin Pharmaceutical, Inc. is a global rare disease biotechnology company focused on delivering medicines for people living with genetically defined conditions. The company has a proven track record of innovation, with nine commercial therapies and a strong clinical and preclinical pipeline. Using a distinctive approach to drug discovery and development, BioMarin seeks to unleash the full potential of genetic science by pursuing category-defining medicines that have a profound impact on patients. The company was founded by John C. Klock, Christopher M. Starr and Grant W. Denison on March 21, 1997 and is headquartered in San Rafael, CA.

Founded: 1997
CEO: Mr. Alexander Hardy
Employees: 3,221
Headquarters: San Rafael, California, United States of America
Fiscal year end: 12-31
Website: biomarin.com

Company profile

Exchange: US
Symbol: BMRN
Market-cap rank: #1379
Listing date: 1970-01-01
Market cap: 10.69B
Float cap: 10.63B
Shares out: 193.57M
Float shares: 192.63M

Sectors & themes

Biotechnology Fractional Shares JP

Browse all sectors & themes

Quote time 2026-10-08 07:00:00 · For reference only, not investment advice and not tailored to your situation.